{
    "Allocation": "N/A",
    "CompleteTime": 24,
    "DesignModel": "Single Group Assignment",
    "DrugInformation": {
        "ArmGroupList": [
            {
                "ArmGroupDescription": "nab-paclitaxel: 260mg/m x 2 cycles , cisplatin: 75mg/m days 1-3 , afatinib: 30mg x 6 weeks(everyday) , ",
                "ArmGroupLabel": "Treatment Cohort",
                "ArmGroupType": "Experimental",
                "InterventionDescription": [
                    {
                        "Dosage": "260mg/m",
                        "DrugName": "nab-paclitaxel",
                        "Duration": "x 2 cycles",
                        "HowToTake": "",
                        "OtherName": [
                            "Albumin-bound paclitaxel",
                            "Abraxane"
                        ]
                    },
                    {
                        "Dosage": "30mg",
                        "DrugName": "afatinib",
                        "Duration": "x 6 weeks(everyday)",
                        "HowToTake": "",
                        "OtherName": []
                    },
                    {
                        "Dosage": "75mg / m",
                        "DrugName": "cisplatin",
                        "Duration": "days 1-3",
                        "HowToTake": "",
                        "OtherName": [
                            "CDDP"
                        ]
                    }
                ],
                "InterventionList": {
                    "ArmGroupInterventionName": [
                        "drug: nab-paclitaxel",
                        "drug: cisplatin",
                        "drug: biological: tislelizumab",
                        "drug: afatinib"
                    ]
                }
            }
        ]
    },
    "Enrollment": "28",
    "InterventionName": "Cisplatin, Tislelizumab",
    "Masking": "None (Open Label)",
    "NCTID": "NCT05516589",
    "Objective": "Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC",
    "OfficialTitle": "Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for the Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial (neoCHANCE-2 Trial)",
    "PopulationBox": {
        "Condition": "Head and Neck Squamous Cell Carcinoma",
        "Gender": "All",
        "HealthyCondition": "No",
        "MaxAge": "",
        "MinAge": "18 Years",
        "Participant": "28"
    },
    "PopulationRatio": "",
    "Title": "Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC",
    "WashoutPeriod": "",
    "_id": "NCT05516589",
    "version": "1.7.1"
}